F-18 fluciclovine PET/CT detects metastatic breast cancer

In this study, Mushtaq and colleagues enrolled 20 women with new or suspected recurrent ILC from a previous trial at Emory University. Patients had undergone PET/CT scans after IV administration of F-18 fluciclovine and Ga-68 PSMA on separate days. For comparison, conventional imaging included CT or bone scans in 13 patients and F-18 FDG-PET in seven patients.An image from Mushtaq's presentation showing a comparison between PET radiotracers in a patient with ILC. Image courtesy of Aliza Mushtaq, MD, Emory University.Three experts assessed radiotracer uptake per patient as well as in three regions per patient: ipsilateral axillary lymph nodes (LN), extra-axillary LNs (ipsilateral supraclavicular, internal mammary), and distant lesions (metastases).Conventional imaging detected metastasis in five patients and in seven out of 60 regions of interest (two axillary, two extra-axillary, and three distant); Ga-68 PSMA-PET/CT detected metastasis in seven patients and in seven of 60 regions (four axillary and three distant); and F-18 fluciclovine detected metastasis in nine patients and in 13 of 60 regions (five axillary, three extra-axillary, and five distant).“F-18 fluciclovine PET/CT has higher detection for metastases compared to [conventional imaging] and Ga-68 PSMA on a patient and region level,” Mushtaq said.Moreover, F-18 fluciclovine PET was positive in all regions positive on PSMA-PET, while in six regions positive on F-18 fluciclovine, Ga-68 PSMA was negative, Mushtaq ad...
Source: AuntMinnie.com Headlines - Category: Radiology Authors: Tags: Molecular Imaging Breast Imaging 2023 Source Type: news